Abstract
Introduction Tuberculosis preventive therapy (TPT) effectively decreases rates of tuberculosis reactivation in people living with HIV (PLHIV) who are at increased risk. The Uganda Ministry of Health launched a 100-day campaign to scale-up TPT in PLHIV in July 2019. We sought to examine the effect of the campaign on trends of TPT uptake and characteristics associated with TPT uptake and TPT completion among persons in HIV care. We retrospectively reviewed routinely collected data from 2016 to 2019 at six urban public health facilities in Uganda.
Methods A cross-sectional review of the HIV care database and paper-based TPT registers at six public health facilities in Kampala, Uganda. Estimated trends of prevalence of TPT (given as Isoniazid preventive therapy [IPT]) uptake and treatment completion across the 4 years, among PLHIV aged 15 years and above, and factors associated, were examined using Poisson regression model with robust standard errors using generalized estimating equation (GEE) models.
Results On average a total of 43,215 patients aged 15 years and above were eligible for TPT each calendar year at the six health facilities. More than 70% were females and median age was 34 years (inter-quartile range 28 to 41 years on overall). There was consistently low TPT uptake from 2016 to 2018, but as expected, the uptake significantly increased by about 25% (relative increase) from 2.5% of eligible PLHIV in 2018 to 64.8% in 2019 (prevalence of TPT uptake 4.5% (1,746/38,704), 4.4% (1,743/39,630), 2.5% (1,018/40,390), and 64.8% (26,478/40,867) during 2016, 2017, 2018 and 2019 respectively). TPT uptake in 2019 was 26.0 times higher compared to that in 2018 (adjusted prevalence ratio [aPR] = 26.0 [95%CI 24.5, 27.7], P-value<0.001). Also, TPT completion was consistently high at about 80% between years 2016 – 2018 but dramatically increased by 17% (relative increase) in 2019 compared to that in 2018 (prevalence of TPT completion was 81.2%, 76.3%, 82.6% and 96.5% in year 2016, 2017, 2018 and 2019 respectively). The increase in TPT completion prevalence from 2018 to 2019 remained significant even after adjusting for patients’ baseline characteristics (aPR [95%CI] = 1.12 [1.04, 1.21], P value=0.003). Not on ART or newly started on ART compared ART experienced were associated with poor TPT completion, whereas older age (≥25 years versus 15-24 years) was associated with higher TPT completion.
Conclusion The targeted 100-day campaign dramatically increased TPT uptake and completion among PLHIV suggesting a viable catch up strategy to meet WHO guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support for data collection was provided by EDCTP TB NODE, grant number: 1) EDCTP-RegNET2015-1104, and 2) Fogarty International Center, National Institutes of Health (grant # 2D43TW009771-06 “HIV and co-infections in Uganda.” The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The AIDS Support Organization Research Ethics Committee (TASOREC), Kampala, Uganda (number: TASOREC/085/19-UG-REC-009) and the Uganda National Council for Science and Technology, Kampala, Uganda (UNCST number: HS729ES) granted ethical approval for the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
Data cannot be shared publicly because of confidentiality. Data are available on request from the Infectious Diseases Insitute, Institutional Data Access / Ethics Committee (contact via musaazijoseph7{at}gmail.com) for researchers who meet the criteria for access to confidential data.
